<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029326</url>
  </required_header>
  <id_info>
    <org_study_id>2009-09-074</org_study_id>
    <nct_id>NCT02029326</nct_id>
  </id_info>
  <brief_title>Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prometheus's Onco dX assay platform provides technological breakthrough for immunoassay by&#xD;
      obtaining a level of sensitivity down to single tumor cells without compromising specificity.&#xD;
      This allows assessment of multiple TKI treatment targets, their activation status, as well as&#xD;
      down stream signaling proteins using very tiny amount of tissue that can be obtained by FNA&#xD;
      or CTCs.&#xD;
&#xD;
      We planned this study to explore biomarkers predictive of clinical response to&#xD;
      cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform. We&#xD;
      will also elucidate signal transduction pathway attributable to cetuximab resistance, monitor&#xD;
      changes in the RTK activation status during cetuximab treatment using circulating tumor cells&#xD;
      and analyze correlation between the quantity of circulating tumor cells and treatment&#xD;
      response to cetuximab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2010</start_date>
  <completion_date type="Actual">August 26, 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform</measure>
    <time_frame>at Screening (Day - 21 ~ 0 ), at 4 weeks and average 6months(end of treatment)</time_frame>
    <description>A. To analyze expression and activation status of receptor tyrosine kinases in signal transduction pathways in FNA samples and circulating tumor cells B. To identify negative predictive markers to cetuximab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. RTK activation status during cetuximab treatment using circulating tumor cells</measure>
    <time_frame>at Screening (Day - 21 ~ 0 ), at 4 weeks and average 6months(end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. signal transduction pathway attributable to cetuximab resistance</measure>
    <time_frame>at Screening (Day - 21 ~ 0 ), at 4 weeks and EOT (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab</measure>
    <time_frame>at Screening (Day - 21 ~ 0 ), at 4 weeks and average 6months (end of treatment)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        colorectal cancer patients who are treated with cetuximab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed metastatic colorectal cancer&#xD;
&#xD;
          -  Cetuximab-based chemotherapy (monotherapy, combination therapy with cytotoxic&#xD;
             chemotherapy such as FOLFOX, XELOX, irinotecan, FOLFIRI, XELIRI, first-line,&#xD;
             second-line or third-line are all eligible)&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  ECOG Performance Status of 0-2&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Signed and dated informed consent before the start of specific protocol procedures.&#xD;
&#xD;
          -  FNA will be performed in patients with feasible biopsy site; ascites or pleural fluid&#xD;
             will be collected in metastatic CRC patients with ascites or pleural effusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active clinically serious infections (&gt; grade 2 CTCAE version 3.0)&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis&#xD;
&#xD;
          -  Radiotherapy during study or within 4 weeks of start of study drug.&#xD;
&#xD;
          -  Prior exposure to the study drug.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>January 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer, cetuximab, biomarker, prometheus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

